Specifically, in small-bowel cancers, MCs can act as major drivers of inflammation through IL-33/ST2-mediated signaling, promoting chronic inflammation and strongly skewing toward a Th17 immune response. The gene discussed is IL33; the disease is small intestine carcinoma.